Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Saved in:
| Title: | Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia. |
|---|---|
| Authors: | Bibikova E; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Parsa S; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Floren M; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Law B; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Clevenger T; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Cheung J; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., De Jesus G; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Burke K; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA., Gulrajani M; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Yamaguchi K; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Do P; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Dougherty B; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA., Whitston D; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA., Brock G; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Munugalavadla V; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Frigault MM; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Hartmann TN; Faculty of Medicine, Department of Medicine I, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany., Byrd JC; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Furman RR; Division of Hematology and Oncology, Weill Cornell Medicine, New York, New York, USA., Brown JR; Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA., Covey T; Hematology, Oncology R&D, AstraZeneca, South San Francisco, California, USA., Mortlock A; Hematology, Oncology R&D, AstraZeneca, Cambridge, UK. |
| Source: | Hematological oncology [Hematol Oncol] 2025 Jan; Vol. 43 (1), pp. e70008. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.70008 |
